Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Marrone Bio's Amplitude Available For 2018 Growing Season

Published 12/13/2017, 08:13 PM
Updated 07/09/2023, 06:31 AM

Marrone Bio Innovations, Inc. (NASDAQ:MBII) has announced the availability of a cost-effective and high-performance biological fungicide, Amplitude, for the 2018 growing season. Utilizing the same active ingredient in the recently EPA-approved Stargus, Amplitude broadens the use of this new product to large acre crops, the company noted.

Amplitude is based on a new strain of Bacillus amyloliquefaciens. It has shown strong performance against soil diseases and white molds including Rhizoctonia (pink rot and black scurf of potatoes), Phytophthora and Fusarium, as revealed in field trials conducted in the United States, Europe and Canada.

Amplitude is the direct result of Marrone Bio’s directed screening discovery program. It is additive and complementary to the broad spectrum of diseases covered by the company’s first biofungicide, Regalia.

According to the company, the unique biofungicide will help growers to control soil diseases and white molds on a vast range of large acre crops, pulses, tuber and root crops.

Marrone Bio and partners are testing this Bacillus-based product for seed treatment applications. Moreover, the company has been issued a patent on the novel strain used in Amplitude. The biofungicide product has also been submitted to Mexico and Canada for approval, while the dossier is being prepared for the European Union.

Potato and pulse crop acres affected by white mold increase every year in the United States. For instance, the yield loss to white mold can easily reach 50% for pulse crops such as lentils. Europe and Canada are expected to grow 6.7 million and 9.3 million hectares of Canola (oilseed rape) in 2017, respectively, and white mold is the most serious disease facing these crops.

Shares of Marrone Bio have declined 16.1% in the past three months, underperforming the industry’s 6.1% growth.

Marrone Bio, during third-quarter earnings, said that it has made a significant progress in penetrating the United States and overseas markets and also remains positive on the long-term outlook of its business. The company also expects its ongoing manufacturing process improvement initiatives in R&D to continue to contribute to an improvement in margins moving ahead.

Zacks Rank & Stocks to Consider

Marrone Bio currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the basic materials space are Westlake Chemical Corporation (NYSE:WLK) , Daqo New Energy Corp. (NYSE:DQ) and Kronos Worldwide Inc. (NYSE:KRO) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.

Westlake Chemical has an expected long-term earnings growth rate of 10.6%. Its shares have moved up 80.7% year to date.

Daqo New Energy has an expected long-term earnings growth rate of 7%. Its shares have surged a whopping 153.5% year to date.

Kronos Worldwide has an expected long-term earnings growth rate of 5%. Its shares have rallied 115.2% year to date.

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>

Kronos Worldwide Inc (KRO): Free Stock Analysis Report

Marrone Bio Innovations, Inc. (MBII): Free Stock Analysis Report

Westlake Chemical Corporation (WLK): Free Stock Analysis Report

DAQO New Energy Corp. (DQ): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.